Shares of Inovio Pharmaceuticals Inc.
were halted and then fell 33.6% when pre-market trading resumed on Monday, when the company said the Phase 2/3 clinical trial for its COVID-19 vaccine candidate was in a “clinical suspension. partial “while answering further questions from the Food and Drug Administration. The suspension is not due to an adverse event, which is what put the phase 3 study on hold for AstraZeneca
and the Oxford University̵
increased by 21.%.